Tumor tissues were collected from 31 patients with ESCC receiving neoadjuvant PD‐1 blockade (camrelizumab) combined with chemotherapy (nab‐paclitaxel and capecitabine).[15] Patients were divided into responder and non‐responder groups according to their response to the combined therapy: patients with tumor regression≥90% were defined as responders (R) and tumor regression<90% as non‐responders (NR).[15] Tissues were collected before and after the neoadjuvant therapy separately, and bulk RNA sequencing was performed on these samples. Here, PDCD1 is linked to neoplasm.